Understanding the Market | ASCLETIS-B rises over 3% and will announce early research results of obesity candidate drug ASC47
I'm PortAI, I can summarize articles.
ASCLETIS-B's stock price rose over 3%, currently reported at HKD 6.55, with a trading volume of HKD 7.4352 million. The company will report early research results of its obesity candidate drug ASC47 at the 32nd European Congress on Obesity. ASC47 has been approved by the FDA for clinical trials, and there are rumors that the World Health Organization will include weight loss drugs in its essential medicines list. CITIC Securities expects the weight loss drug sector to welcome a thematic market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments